ARTICLE | Clinical News
Provenge (APC8015): Completed Phase III study enrollment
September 10, 2001 7:00 AM UTC
Dendreon Corp. (DNDN), Seattle, Wash. Product: Provenge ( APC8015) Business: Cancer Therapeutic category: Immune stimulation Target: T cells Description: Activated autologous dendritic cell therapy I...